The World Health Organization has prequalified a multi-dose vial version of the maternal RSV vaccine, clearing the last regulatory obstacle that had been holding up a funded global rollout aimed at protecting newborns in the countries where RSV kills the most infants.
The decision, announced on September 9, covers the multi-dose presentation of RSVpreF, sold by Pfizer as Abrysvo. Gavi, the vaccine alliance, welcomed the decision and said it paves the way for introduction in lower-income countries with its support.